The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease

B R Bloem; I Irwin; O J Buruma; J Haan; R A Roos; J W Tetrud; J W Langston

doi:10.1016/0022-510x(90)90225-c

The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease

J Neurol Sci. 1990 Jul;97(2-3):273-93. doi: 10.1016/0022-510x(90)90225-c.

Authors

B R Bloem¹, I Irwin, O J Buruma, J Haan, R A Roos, J W Tetrud, J W Langston

Affiliation

¹ Department of Neurology, University Hospital of Leiden, The Netherlands.

PMID: 2205710
DOI: 10.1016/0022-510x(90)90225-c

Abstract

In human and subhuman primates, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces irreversible clinical, biochemical and neuropathological alterations highly reminiscent of those observed in Parkinson's disease. The MPTP model has provided the best available tool to date for the assessment of efficacy and side-effects of symptomatic treatments of Parkinson's disease. In addition, the mechanism of action of MPTP has offered a basis for the development of novel therapeutic strategies aimed at the prevention of Parkinson's disease.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine*
Animals
Disease Models, Animal
Humans
Parkinson Disease, Secondary / chemically induced
Parkinson Disease, Secondary / physiopathology*

Substances

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine